Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. It is creating an improved model for successful rare disease drug development that increases efficiency and effectiveness by changing the way the process is organized and conducted. The Company believes that it can deliver significant value to its patients by building a diverse and high quality pipeline of rare disease therapeutics and efficiently transforming good science into great medicine. 

Type
Public
HQ
Novato, US
Founded
2010
Size (employees)
376 (est)
Ultragenyx Pharmaceutical was founded in 2010 and is headquartered in Novato, US
Report incorrect company information

Key People/Management at Ultragenyx Pharmaceutical

Emil D. Kakkis M.D., Ph.D

Emil D. Kakkis M.D., Ph.D

Chief Executive Officer and President
Camille Bedrosian M.D

Camille Bedrosian M.D

Chief Medical Officer and Executive Vice President
Jayson Dallas M.D

Jayson Dallas M.D

Chief Commercial Officer and Executive Vice President
Dennis Huang

Dennis Huang

Chief Technical Operations Officer and Executive Vice President
Thomas Kassberg

Thomas Kassberg

Chief Business Officer and Executive Vice President
Karah Parschauer

Karah Parschauer

General Counsel and Executive Vice President
Show more

Ultragenyx Pharmaceutical Office Locations

Ultragenyx Pharmaceutical has an office in Novato
Novato, US (HQ)
60 Leveroni Ct
Show all (1)
Report incorrect company information

Ultragenyx Pharmaceutical Financials and Metrics

Ultragenyx Pharmaceutical Financials

Ultragenyx Pharmaceutical's revenue was reported to be $133 k in FY, 2016
USD

Revenue (Q1, 2018)

10.7 m

Gross profit (Q1, 2018)

10.5 m

Gross profit margin (Q1, 2018), %

97.9%

Net income (Q1, 2018)

30.3 m

EBIT (Q1, 2018)

(96.5 m)

Market capitalization (15-Jun-2018)

4.1 b

Closing share price (15-Jun-2018)

82.7

Cash (31-Mar-2018)

226.7 m
Ultragenyx Pharmaceutical's current market capitalization is $4.1 b.
Annual
USDFY, 2014FY, 2015FY, 2016

Revenue

133 k

General and administrative expense

10.8 m33 m64.9 m

R&D expense

46 m114.7 m183.2 m

Operating expense total

56.8 m147.7 m248.1 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

17 k111 k17 k10.7 m

Cost of goods sold

225 k

Gross profit

10.5 m

Gross profit Margin, %

98%
Annual
USDFY, 2014FY, 2015FY, 2016

Cash

24.3 m93.6 m161.1 m

Inventories

5.9 m13.1 m20.1 m

Current Assets

193.4 m450.2 m401.7 m

PP&E

3 m7.4 m17.1 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

178 m52.4 m166.7 m70.8 m55.1 m142.3 m159.5 m90.8 m226.7 m

Accounts Receivable

3.7 m

Inventories

2.1 m

Current Assets

350.5 m336.5 m460.7 m430.2 m411.1 m416.8 m444.7 m419.8 m581.6 m
Annual
USDFY, 2014FY, 2015FY, 2016

Net Income

(59.8 m)(145.6 m)(245.9 m)

Depreciation and Amortization

684 k1.4 m3.4 m

Inventories

(4.1 m)(7.1 m)(7.1 m)

Accounts Payable

3.2 m(2 m)2.5 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(21.4 m)(29.8 m)(39.2 m)(52.8 m)(56.9 m)(64.9 m)(68.3 m)30.3 m

Depreciation and Amortization

6.2 m

Accounts Payable

3.5 m3.6 m4.2 m5.8 m10.2 m4.4 m6 m7 m6.6 m8.3 m(1.3 m)

Cash From Operating Activities

(89.5 m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

Ultragenyx Pharmaceutical News and Updates

Report incorrect company information